PHGDH and metabolic syndrome: Our study showed that the expression levels of oxidoreductases, including d-3-phosphoglycerate dehydrogenase (PHGDH) and malate dehydrogenase (MDH1), were also decreased at the symptomatic stage of the metabolic syndrome, which may further worsen oxidative stress.